Insider · CIK 0001575745

Jovan-Embiricos Morana

Reports to the SEC for 4 companies · BERKELEY HEIGHTS, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001575745

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-03	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2025-04-10	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2024-06-06	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+35K sh	—	—	100,197
2023-05-11	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+35K sh	—	—	65,197
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+685K sh	$4.61	+$3.16M	2,059,884
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+325K sh	$4.61	+$1.5M	668,072
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+1.63M sh	$4.61	+$7.5M	2,038,583
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+1.39M sh	$4.61	+$6.43M	4,193,874
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+868K sh	$4.61	+$4M	867,678
2022-07-28	KLRSKalaris Therapeutics, Inc.A Award	Director	AAward	+3.25M sh	$4.61	+$15M	16,674,766
2022-06-24	CGEMCullinan Therapeutics, Inc.M Exercise/Conversion	10% Owner	MExercise/Conversion	+105K sh	$4.30	+$451K	217,352
2022-06-24	CGEMCullinan Therapeutics, Inc.M Exercise/Conversion	10% Owner	MExercise/Conversion	+35.5K sh	$4.30	+$153K	252,881
2022-06-24	CGEMCullinan Therapeutics, Inc.F Tax Payment	10% Owner	FTax Payment	−45.1K sh	$13.39	−$604K	207,803
2022-06-24	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	10% Owner	MExercise/Conversion	−105K sh	—	—	0
2022-06-24	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	10% Owner	MExercise/Conversion	−35.5K sh	—	—	0
2022-05-17	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.5K sh	—	—	27,500
2021-11-10	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−680 sh	$24.77	−$16.8K	1,375,262
2021-11-10	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−120 sh	$24.77	−$2,971.8	342,693
2021-11-09	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−3,243 sh	$24.79	−$80.4K	1,375,942
2021-11-09	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−572 sh	$24.79	−$14.2K	342,813
2021-11-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−7,124 sh	$24.80	−$177K	1,379,185
2021-11-05	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,257 sh	$24.80	−$31.2K	343,385
2021-10-27	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,870 sh	$24.78	−$46.3K	1,386,309
2021-10-27	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−330 sh	$24.78	−$8,176.575	344,642
2021-10-25	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−6,604 sh	$24.82	−$164K	1,388,179
2021-10-25	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−1,165 sh	$24.82	−$28.9K	344,972
2021-10-22	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−4,864 sh	$24.77	−$120K	1,394,783
2021-10-22	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−859 sh	$24.77	−$21.3K	346,137
2021-10-21	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−85 sh	$24.75	−$2,103.75	1,399,647
2021-10-21	KLRSKalaris Therapeutics, Inc.S Sale	Director	SSale	−15 sh	$24.75	−$371.25	346,996
2021-09-16	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	10% Owner	AAward	+7,800 sh	—	—	7,800
2021-05-25	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+1.14M sh	—	—	1,136,525
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+2.91M sh	—	—	2,912,345
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+639K sh	—	—	639,295
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+455K sh	—	—	455,338
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+182K sh	—	—	182,135
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+71.6K sh	—	—	526,937
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+143K sh	—	—	325,333
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+71.6K sh	—	—	71,599
2021-01-12	CGEMCullinan Therapeutics, Inc.C Conversion	10% Owner	CConversion	+215K sh	—	—	214,798
2021-01-12	CGEMCullinan Therapeutics, Inc.P Purchase	10% Owner	PPurchase	+95.2K sh	$21.00	+$2M	622,175
2021-01-12	CGEMCullinan Therapeutics, Inc.P Purchase	10% Owner	PPurchase	+105K sh	$21.00	+$2.2M	104,762
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series Seed Convertible Preferred StockC Conversion	10% Owner	CConversion	−8M sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−20.5M sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−4.5M sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−3.21M sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−1.28M sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series C Convertible Preferred StockC Conversion	10% Owner	CConversion	−504K sh	—	—	0
2021-01-12	CGEMCullinan Therapeutics, Inc. · Series C Convertible Preferred StockC Conversion	10% Owner	CConversion	−1.01M sh	—	—	0

Recent filings

Accepted (ET)
Jun 44
Jovan-Embiricos Morana0001193125-26-257564
SEC(opens sec.gov)
Apr 114
Jovan-Embiricos Morana0000950170-25-053372
SEC(opens sec.gov)
Jun 74
Jovan-Embiricos Morana0000950170-24-070602
SEC(opens sec.gov)
May 124
Jovan-Embiricos Morana0001209191-23-029095
SEC(opens sec.gov)
Aug 14
Jovan-Embiricos Morana0000899243-22-027171
SEC(opens sec.gov)
Jun 284
Jovan-Embiricos Morana0001104659-22-075392
SEC(opens sec.gov)
May 194
Jovan-Embiricos Morana0000899243-22-018836
SEC(opens sec.gov)
Mar 254
Jovan-Embiricos Morana0000899243-22-012373
SEC(opens sec.gov)
Nov 154
Jovan-Embiricos Morana0000899243-21-044619
SEC(opens sec.gov)
Nov 94
Jovan-Embiricos Morana0000899243-21-043670
SEC(opens sec.gov)

Companies

Address

C/O KALARIS THERAPEUTICS, INC. 400 CONNELL DRIVE, SUITE 5500

BERKELEY HEIGHTS, NJ, 07922